Melanoma Matters – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Melanoma Matters

Melanoma Matters Pod

Forme & Santé

Fréquence : 1 épisode/7j. Total Éps: 87

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 09/07/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇬🇧 Grande Bretagne - Medicine
09/07/2026
#83
🇬🇧 Grande Bretagne - Medicine
18/03/2026
#99
🇨🇦 Canada - Medicine
05/03/2026
#85
🇨🇦 Canada - Medicine
03/03/2026
#55
🇨🇦 Canada - Medicine
02/03/2026
#39
🇨🇦 Canada - Medicine
01/03/2026
#27
🇨🇦 Canada - Medicine
28/02/2026
#22
🇬🇧 Grande Bretagne - Medicine
27/09/2025
#97
🇬🇧 Grande Bretagne - Medicine
26/09/2025
#65
🇬🇧 Grande Bretagne - Medicine
12/09/2025
#84

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.youtube.com/watch?v=29KTF6Rpvy8
1 partage

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

Correct

Score global : 73%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Ep 83: Guest Megan Othus and Time of Day Administration

Saison 2 · Épisode 83

mercredi 24 juin 2026 • Durée 40:12

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.

Megan talks about growing up in the PNW and going East to get back West. She helps us digest the time of day analyses and some of the missing analyses that should have been shown in the papers published to date. She teaches us about confounders, accounting for multiple comparisons, and guarantee time bias.

Lire plusRéduire

Ep 82: Best of ASCO: 2026

Saison 2 · Épisode 82

samedi 13 juin 2026 • Durée 01:04:04

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.

They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.

Studies discussed include:

OptimUM-02 phase 2/3 trial for metastatic uveal melanoma
ADAM phase 3 trial for MCC
5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)
Pilot neoadjuvant studies (NeoReNi, NeoINR)
Time of day of infusion and immunotherapy efficacy

Lire plusRéduire

Live from ASCO 2026: a preview

Saison 2 · Épisode 82

lundi 1 juin 2026 • Durée 06:15

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.

OptimUM-02

ADAM

KN-942

Neoadjuvant pilot studies

... and more

Lire plusRéduire

Ep 81: IGNYTE trial (RP1 + nivo)

Saison 3 · Épisode 81

vendredi 13 février 2026 • Durée 32:38

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).Takeaways

Clinical Trial Data
Treatment Efficacy

Chapters

00:00 Introduction to IGNYTE Study
14:04 Response Rate and Safety Profile
25:17 RNA-seq Analysis and Toxicity

Lire plusRéduire

Ep 80: 2025 Holiday Special

Saison 2 · Épisode 80

mardi 30 décembre 2025 • Durée 35:32

Summary

Happy Holidays and Festive Season Everyone!

In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music, books, plays, and television shows. They share personal anecdotes about memorable trips, culinary highlights, gym feats, and their podcasting journey, while also looking ahead to their goals and aspirations for 2026.

Keywords

movies, music, books, plays, television, travel, culinary, podcast, goals, aspirations, Happy Holidays, 2025, reflections, best

Takeaways

"Culture"

James and Sapna read a lot of books.

Theatrical performances can be a delightful family experience - James highly recommends Matilda.

There is lots of television watching on both sides of the pond.

Traveling memories in 2025.

Culinary adventures include Ottolenghi in Richmond.

Podcasting is fun when you do it with your best friend.

Chapters

00:00 Festive Reflections and Year-End Special

02:50 Movies and Theater Experiences

09:32 Books he read & bought for others to read

12:29 Books she read or audio'ed

15:56 TV shows we watched in 2025

Ep 79: coBRIM, COMBI-d 5-year follow-up

Saison 2 · Épisode 79

lundi 29 décembre 2025 • Durée 36:09

Summary

In this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of studies such as coBRIM, COMBI-d, and how those compare to 5-year benchmarks from the COLUMBUS study. They explore subgroups and characteristics of favorable (and durable) response, the role of MEK inhibitors on immune activation, and a potential fellow's project (looking at you, Rob?).

Keywords

Melanoma, targeted therapy, co-BRIM, COMBI-d, COLUMBUS, immunotherapy, BRAF MEK inhibitors, overall survival, progression-free survival, patient outcomes, cohorts, LDH, organ sites

Takeaways

MEK inhibitors have a complex role in immune response.

Normal LDH levels correlate with better patient outcomes.

Immunotherapy and targeted therapy can have overlapping patient populations.

Sound Bites

"We thought we'd do more targeted therapy"

"Normal LDH is doing better."

"Long-term follow-up for targeted therapy."

Chapters

00:00 Will he or won't he ... James awaits invitation to film premiere

04:26 coBRIM 5y FU

Ep 78 TRAILER: MEK inhibitor trials

Saison 2 · Épisode 78

lundi 29 décembre 2025 • Durée 01:06

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

Saison 2 · Épisode 78

lundi 29 décembre 2025 • Durée 37:03

Summary

So many shoutouts in this episode of Melanoma Matters!

Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation was derived.

Keywords

targeted therapy, MEK inhibitors, METRIC, NEMO, pimasertib, NRAS, BRAF, melanoma, oncology, side effects, clinical trials, drug approval, patient care, cancer treatment, Owen, Dave Solit, Tom Newsom-Davis, Peter Hill

Takeaways

Targeted therapy is an important area of focus in oncology.

MEK inhibitors have been in development for over 15 years.

The NEMO trial aimed to evaluate binimetinib for NRAS mutant melanoma.

PFS as a primary endpoint in clinical trials.

Side effects of MEK inhibitors.

The NEMO trial faced challenges in gaining FDA approval despite positive results.

Sound Bites

Ep 77: Guest Merrick Ross

Saison 2 · Épisode 77

lundi 29 décembre 2025 • Durée 44:38

Summary

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Merrick Ross, a seasoned surgical oncologist, discussing his background, the evolution of surgical practice with regards to melanoma treatment, and the importance of multidisciplinary collaboration. They explore innovations in neoadjuvant therapy, the critical role of pathology in treatment decisions, and the future directions of surgical approaches in metastatic melanoma. They discuss the need for continuous adaptation and collaboration in the ever-evolving landscape of melanoma treatment.

Keywords

melanoma, surgical oncology, neoadjuvant therapy, multidisciplinary care, pathology, metastatic melanoma, melanoma treatment, melanoma surgery, immunotherapy, clinical trials

Takeaways

Merrick Ross shares his journey from Chicago to surgical oncology.

Surgery for melanoma has evolved from a primary modality to a multimodal approach.

The importance of collaboration between surgical oncologists and medical oncologists is emphasized.

Neoadjuvant therapy is seen as a promising area for future research and treatment.

Ultrasound imaging is more effective than cross-sectional imaging for assessing nodal basins.

The role of pathology is crucial in understanding treatment responses and guiding future therapy.

Surgical decisions should be tailored based on individual patient responses and disease characteristics.

The need for less aggressive surgical interventions is highlighted as treatment evolves.

Merrick emphasizes the importance of understanding tumor biology in surgical decision-making.

Ep 76: KEYNOTE 054 7-year follow-up

Saison 2 · Épisode 76

dimanche 28 décembre 2025 • Durée 28:49

Summary

In this Episode, hosts James & Sapna go into the 7-year follow-up from the randomized phase 3 adjuvant trial of pembrolizumab versus placebo for stage III melanoma, KEYNOTE-054

There's a bit too much talk about weightlifting though...

Lire plusRéduire

Podcasts et contenus similaires

Autres podcasts ou contenus associés partageant des thèmes ou audiences similaires.

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Melanoma Matters. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

Il n'y a pas de contenu associé à ce podcast.

À propos Méthodologie Contact Me soutenir Politique de confidentialité Mentions légales

Melanoma Matters – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Youtube1

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Podcasts Similaires Basées sur le Contenu

Youtube1

Apple Podcasts

Spotify